The 4Kscore Test would benefit any patient for whom additional information about their risk (probability) of having aggressive cancer would enhance clinical decision-making before deciding to perform a prostate biopsy.
The 4Kscore Test does not provide a diagnosis of prostate cancer. Rather, it is designed to help clarify the decision on whether or not to perform a biopsy based on the probability of a patient having aggressive prostate cancer.
Who is not a candidate for this test?
- Previous diagnosis of prostate cancer
- Patient who has received a DRE in the previous 96 hours (4 days) before phlebotomy. A DRE performed after the phlebotomy is acceptable
- Patient on 5-alpha reductase inhibitor (5-ARI) therapy, such as Avodart® (dutasteride) or Proscar® (finasteride), within the previous six (6) months
- Patient who has undergone any procedure or therapy to treat symptomatic BPH or any invasive, urologic procedure that may be associated with a secondary PSA elevation prior to phlebotomy within the previous six (6) months